CD5-positive DLBCL is a less common subtype of diffuse large B-cell lymphoma (DLBCL) that can be more aggressive and harder to treat. While specific treatment guidelines for this subtype are still evolving, it is generally treated similarly to other forms of DLBCL.
The standard first-line treatment is typically R-CHOP Show Full Answer
CD5-positive DLBCL is a less common subtype of diffuse large B-cell lymphoma (DLBCL) that can be more aggressive and harder to treat. While specific treatment guidelines for this subtype are still evolving, it is generally treated similarly to other forms of DLBCL.
The standard first-line treatment is typically R-CHOP, which includes:
- Rituximab (Rituxan)
- Cyclophosphamide
- Doxorubicin
- Vincristine
- Prednisone
Another FDA-approved first-line option is Pola-R-CHP, which replaces vincristine with polatuzumab vedotin (Polivy) and has shown strong results in advanced DLBCL. Because CD5-positive DLBCL carries a higher risk of relapse, including in the central nervous system (CNS), doctors may also consider preventive chemotherapy injected into the spinal fluid, such as methotrexate.
If the disease relapses or doesn't respond to first-line treatment, options may include:
- CAR T-cell therapy (e.g., Yescarta, Breyanzi, or Kymriah)
- Bispecific antibody therapy (e.g., Epkinly or Columvi)
- Bone marrow transplant (for eligible patients)
- Clinical trials for newer immunotherapy approaches
It's really important to discuss your specific subtype with your oncologist, as they can tailor a treatment plan based on your individual situation and risk factors.
May 12
Join
Your Privacy Choices
